A reduced dosage of rituximab maintenance therapy may be effective at preventing relapses among people with ANCA-associated vasculitis (AAV),…
Articles by Marisa Wexler, MS
Treatment with ChemoCentryx’s investigational therapy avacopan can improve kidney function in people with ANCA-associated vasculitis to…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
The antibody rituximab is a good alternative to cyclophosphamide for inducing remission in people with ANCA-associated vasculitis (AAV), and…
Use of avacopan can increase remission rates and improve kidney function in people with ANCA-associated vasculitis (AAV), while…
The risk factors that predict serious infections in people with ANCA-associated vasculitis (AAV) vary with time, a study found.
New statistical models could help to predict the risk of relapse and infection following ongoing rituximab treatment in people with…
A survey is seeking people with ANCA-associated vasculitis (AAV) around the world to help researchers better understand how patients…
Genetic variations in the TERT and DSP genes, previously associated with an increased risk of idiopathic pulmonary fibrosis (IPF),…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of…